Clinical trial registry record

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Withdrawn.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 13, 2019.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03446144
Last registry update
August 13, 2019
Status
Withdrawn
Phase
Phase 2
Sponsor
Ionis Pharmaceuticals, Inc.
Enrollment
0
Countries
United States, Australia, New Zealand
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
0
Population
ALL · 55 Years
Duration
2018-03-16 to 2018-10-10
Intervention
IONIS-FB-Lrx; Placebo (sterline saline 0.9%)
Comparator
Placebo (sterile saline 0.9%)
Outcomes measured
Efficacy of IONIS-FB-Lrx — Up to 74 weeks; Incidence and severity of adverse events that are related to treatment with IONIS-FB-Lrx — Up to 86 weeks; Proportion of patients in each treatment group achieving a >50% reduction of plasma complement factor B — Up to 74 weeks; Effect of IONIS-FB-Lrx on the rate of change of the area of GA secondary to AMD — Up to 74 weeks; Effect of factor B reduction on other components of the complement pathways in AMD patients — Up to 74 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON